Single cell and spatial transcriptomics are changing how we understand disease biology and test therapeutic hypotheses.
In this webinar, 10x Genomics will cover technologies implemented at both ends of the pipeline: de-risking targets and mechanisms in proof-of-concept drug development, and generating translational readouts that inform patient stratification and exploratory clinical trial endpoints. We will also preview the next wave of technology, including GEM-X Multiome and VIPerturb-seq, and what these advances mean for researchers building biomarker and mechanism-of-action strategies.
Propath UK will showcase an exploration of tumour heterogeneity and a sample-to-insight pipeline for identifying putative therapeutic targets from 10x Genomics Xenium data. Through a case study comparing primary and metastatic tumours, utilising a custom single cell transcriptomics panel including tertiary lymphoid structure (TLS) and fibroblast signatures, Propath will highlight tumour-cell populations enriched in metastatic lesions. They will explore how the distinct molecular profiles of these populations could reveal mechanisms associated with metastatic progression and potential vulnerabilities for therapeutic intervention in primary disease.
Attendees will leave with a clear view of where these tools fit in their own programmes and how to start applying them.
Kelly Hunter is Chief Scientific Officer at Propath UK, where he leads the company’s scientific strategy and development of advanced spatial biology services across spatial proteomics, spatial transcriptomics, multiplex immunofluorescence and single-cell spatial analysis. With substantial experience in implementing and commercialising cutting-edge tissue profiling technologies, Kelly works closely with pharmaceutical and biotechnology partners to design translational research and biomarker strategies that generate meaningful, decision-ready data from limited clinical samples. His expertise spans complex assay development, custom high-plex panel design, spatial multiomics workflows and the integration of robust bioinformatics to translate rich tissue data into actionable biological insight. At Propath, Kelly helps clients apply responsive, GCP-compliant spatial biology solutions to support mechanism-of-action studies, biomarker discovery, clinical trial delivery and confident decision-making across the drug development pipeline.
